Drug intelligence / Profile preview

Canex T

Development stage
Unknown
Lead developer
Cantex Pharmaceuticals
Modality
Small Molecules
Administration
Topical
01

Overview

Canex T is an over-the-counter (OTC) topical antifungal cream developed and marketed by Shanur Healthcare, a pharmaceutical company based in South Africa. The active ingredient is clotrimazole, a broad-spectrum imidazole antifungal agent. Clotrimazole works by inhibiting the fungal enzyme lanosterol 14-alpha-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. This inhibition leads to increased membrane permeability and the eventual death of the fungal organism. Canex T is indicated for the treatment of various dermatomycoses, including ringworm (tinea corporis), athlete's foot (tinea pedis), jock itch (tinea cruris), pityriasis versicolor, erythrasma, and fungal nail infections such as paronychia. The cream is formulated to be odorless, non-staining, and easily washable, and it is typically applied topically two to three times daily.

Brand names
Canex T
Other names
clotrimazole
02

Targets

CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on Canex T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Canex T.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call